Endoscopic Submucosal Dissection (ESD)
Customize your policy alerts
Sign up for priority health Policy 91617 alerts
Get alerted when Policy 91617 changes without checking for updates manually.
Monitor payer policy activity
This policy describes Priority Health coverage criteria for conventional (non-robotic) endoscopic submucosal dissection (ESD) for select gastrointestinal lesions and identifies when ESD is medically necessary, not medically necessary, or investigational. It applies to providers submitting claims to Priority Health members.
Added site specific exclusions per society guidelines
Added Robotic-assisted/computer-enhanced ESD platforms are explicitly classified as experimental/investigational
Updated Gastric Region indications as they were broad and aligned them with society guidelines
Colon/Rectum criteria changed from size-alone to morphology plus suspected submucosal invasion (SMI)
Duodenum/Small bowel broad coverage eliminated and aligned with ESGE and NCCN medical necessity criteria
Replaced broad indications with guideline-style inclusion features and split esophageal indications into distinct pathways for squamous cell carcinoma and adenocarcinoma/Barrett's dysplasia
Reorganized criteria into general requirements plus detailed site-specific criteria and replaced vague indications with explicit guideline-based thresholds
Medical Necessity and Exclusions for ESD
General Requirements (applies to all sites)
Conventional (non-robotic) ESD may be considered medically necessary when ALL of the following are met:
Applies to conventional (non-robotic) ESD at all anatomic sites.
Esophageal Squamous Cell Carcinoma and Esophageal Dysplasia
ESD may be considered medically necessary when ALL of the following are met:
Site-specific esophageal squamous cell carcinoma and dysplasia criteria.
Early-Stage (T1) Esophageal Adenocarcinoma and Barrett's Esophagus Dysplasia
ESD may be considered medically necessary when ALL of the following are met:
Applies to early-stage (T1) esophageal adenocarcinoma and Barrett's esophagus dysplasia.
Stomach - Early Gastric Adenocarcinoma
ESD may be considered medically necessary when ALL of the following are met:
Applies to early gastric adenocarcinoma per site-specific criteria.
Colon and Rectum - Superficial Colorectal Neoplasia
ESD may be considered medically necessary when ALL of the following are met:
Applies to superficial colorectal neoplasia of the colon and rectum.
Duodenal/Small-Bowel
ESD may be considered medically necessary for select non-ampullary duodenal or small-bowel lesions when ALL of the following are met:
Non-ampullary lesions only; en bloc resection required when EMR cannot achieve it.
Not Medically Necessary — Duodenal/Small-Bowel ESD
Duodenal or small-bowel ESD is considered experimental/investigational/unproven and not medically necessary when performed outside the medical necessity criteria in this policy, including when ANY of the following apply:
Each listed condition individually renders duodenal/small-bowel ESD experimental/investigational/unproven per policy.
Conventional (non-robotic) ESD is not medically necessary when the patient is not a candidate for procedural sedation or anesthesia, when the lesion is ulcerated with endoscopic or histologic features indicating a high risk of lymph‑node metastasis or non‑curative endoscopic resection, or when there is evidence of disease that exceeds accepted early‑stage criteria.
For gastric lesions, ESD is not medically necessary when any of the following are present: poorly differentiated or undifferentiated histology, deep submucosal invasion, ulceration with features indicating an increased risk of lymph‑node metastasis that place the lesion outside accepted curative ESD criteria, or regional lymph‑node or distant metastatic disease.
For esophageal lesions, ESD is not medically necessary when any of the following apply: poorly differentiated or undifferentiated histology, deep submucosal invasion including disease beyond superficial T1b (SM1) when SM1 criteria are not met, ulcerated lesions with features indicating increased lymph‑node metastasis risk outside curative ESD criteria, or regional lymph‑node or distant metastatic disease.
For colon and rectal lesions, ESD is not medically necessary when based on size alone (for example, lesions ≥20 mm) without accompanying endoscopic features that suggest superficial submucosal invasion or without documented inability to reliably achieve en bloc or complete resection with snare‑based EMR.
Robotic‑assisted or computer‑enhanced endoluminal systems designed to perform or assist ESD (for example, the EndoQuest Endoluminal Surgical [ELS] System) are classified as experimental and investigational and are not medically necessary. These systems remain under investigational evaluation and do not have FDA marketing authorization for performing or assisting ESD.
Duodenal or small‑bowel ESD is considered experimental, investigational, and/or unproven and therefore not medically necessary when performed for ampullary lesions, when there is suspected or confirmed deep submucosal invasion, when used routinely or broadly, when applied to lesions for which EMR is appropriate and expected to achieve complete resection, or when performed for training or case‑volume building rather than patient‑specific medical necessity.
The policy now includes additional site‑specific exclusions added in alignment with professional society guidance. Individual site exclusions are detailed elsewhere in the policy under the applicable anatomic section.
Robotic‑assisted and other computer‑enhanced ESD platforms have been explicitly classified as experimental/investigational and are excluded from coverage under this policy.
Conventional (non‑robotic) ESD is not medically necessary when the patient cannot safely undergo procedural sedation or anesthesia, or when the lesion is ulcerated with endoscopic or histologic features that predict a high risk of lymph‑node metastasis or non‑curative resection, or when disease exceeds accepted early‑stage criteria.
If post‑procedure pathology demonstrates findings indicative of non‑curative ESD—such as positive margins (non‑R0 resection), lymphovascular invasion (LVI), deep submucosal invasion (≥ sm2), or poorly differentiated carcinoma—the ESD is not considered definitive therapy and the procedure will be deemed not medically necessary as sole therapy; additional surgical or oncologic management is indicated.
Robotic‑assisted/computer‑enhanced ESD systems and duodenal/small‑bowel ESD performed outside the specific medical necessity criteria in this policy are considered experimental, investigational, and/or unproven and are not medically necessary.
Duodenal or small‑bowel ESD is explicitly listed as not medically necessary (experimental/investigational/unproven) when performed under the conditions specified in the Not Medically Necessary section, including suspected deep invasion, ampullary lesions, routine/widespread use, lesions appropriate for EMR, or use for training rather than individualized medical need.
Previous broad, size‑based indications and vague statements have been removed and replaced with explicit, guideline‑style inclusion features (size, histology, ulceration status, invasion depth, and need for en‑bloc resection). Site‑specific criteria now drive coverage decisions rather than size‑alone rules.
Procedure and Diagnosis Codes
| C9779 | Endoscopic submucosal dissection (ESD), including endoscopy or colonoscopy, mucosal closure, when performed (billable by Facility only). |
| 43499 | Unlisted procedure, esophagus |
| 43999 | Unlisted procedure, stomach |
| 44799 | Unlisted procedure, small intestine |
| 45399 | Unlisted procedure, colon |
| 45999 | Unlisted procedure, rectum |
| C15.3 - C15.9 | Malignant neoplasm of esophagus (range) |
| C16.0 - C16.9 | Malignant neoplasm of stomach (range) |
| C17.0 | Malignant neoplasm of duodenum |
| C18.0 - C18.9 | Malignant neoplasm of colon (range) |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| D00.1 | Carcinoma in situ of esophagus |
| D00.2 | Carcinoma in situ of stomach |
| D13.2 | Benign neoplasm of duodenum / Neoplasm of uncertain behavior of other specified sites |
| D48.7 | Neoplasm of uncertain behavior of other specified sites |
Prior Authorization, Documentation, and Denial Risks
Obtain prior authorization when required and demonstrate eligibility
Conventional (non-robotic) ESD may be considered medically necessary only when general requirements and the applicable site‑specific criteria are met; providers should obtain prior authorization where required by the member’s plan and supply clinical evidence per the documentation requirements.
- Conventional (non-robotic) ESD eligible when all General Requirements are met (high‑definition white‑light endoscopy with chromoendoscopy; lesion appropriate for endoscopic resection; en‑bloc resection required and not achievable with EMR; no distant metastatic disease).
Submit detailed prior authorization request demonstrating medical necessity
When prior authorization is required, submit a medical necessity request that includes clinical evidence showing the lesion evaluation, prior EMR attempts or rationale that EMR is inappropriate, and site‑specific features that meet the policy criteria.
- The request must demonstrate medical necessity per Priority Health Provider Manual guidance.
- Include documentation that EMR was attempted or is unlikely to achieve en‑bloc/complete resection when applicable.
Ensure site‑specific prior authorization aligns with guideline criteria
Prior authorization decisions should be based on updated, site‑specific medical necessity criteria aligned with society guidance for each anatomic site (esophagus, stomach, colon/rectum, duodenum/small bowel).
- Site‑specific thresholds include size, histology, ulceration status, depth of invasion, and need for en‑bloc resection as specified in the policy.
Document EMR was considered or attempted and found unsuitable
Document that EMR was considered and is inappropriate or unlikely to achieve en‑bloc/complete resection before performing ESD; include reasons such as non‑lifting, fibrosis, recurrent/residual lesion after prior EMR, or lesion morphology where piecemeal resection would compromise pathology.
- For duodenal/small‑bowel lesions, explicitly document why EMR is not appropriate or unlikely to succeed (e.g., non‑lifting, submucosal fibrosis, recurrent lesion).
Include supporting clinical and claims documentation with requests
(See Required Clinical Documentation and Claims Documentation callouts for details on required evidence to include with prior authorization and claims.)
Reference updated policy organization and site sections in submissions
Policy reorganized to site‑specific criteria; when submitting requests, reference the updated policy sections for the anatomic site being treated and include evidence mapped to those criteria.
- Refer to the specific Esophagus, Stomach, Colon/Rectum, or Duodenum/Small‑Bowel sections of the policy when justifying medical necessity.
Submit required clinical documentation with prior authorization
Provide clinical documentation demonstrating lesion evaluation with high‑definition white‑light endoscopy plus chromoendoscopy (virtual or dye‑based), site‑specific characterization (size, differentiation, ulceration, invasion depth), that en‑bloc resection is required and cannot be reliably achieved with EMR, and absence of distant metastatic disease.
- Include endoscopic imaging reports (HD white‑light and chromoendoscopy) and histopathology reports showing differentiation status.
- State explicitly that en‑bloc resection is required and why EMR cannot achieve it.
Include explanatory notes for unlisted procedure codes on claims
When billing with unlisted CPT codes (43499, 43999, 44799, 45399, 45999) or facility CPT C9779, include explanatory notes on the claim describing the procedure performed and clinical rationale; prior authorization may be required.
- Explanatory notes must accompany claims billed with unlisted codes as noted in the CPT/HCPCS section.
- Facility billing for ESD may use C9779 where applicable.
Document site‑specific thresholds and map evidence to site criteria
When submitting prior authorization, document site‑specific guideline‑based thresholds used to justify ESD (e.g., lesion size thresholds, histology, ulceration status, depth of invasion, and explicit need for en‑bloc resection) mapped to the policy’s anatomic site criteria.
- Esophageal SCC/dysplasia: >15 mm or smaller but not amenable to en‑bloc EMR.
- Esophageal adenocarcinoma/BE: >20 mm or ≤20 mm not amenable to en‑bloc EMR.
- Stomach: ≤30 mm with intestinal‑type, well/moderately differentiated.
- Colon/rectum: >20 mm with high‑risk morphology and need for en‑bloc resection.
Be aware of general denial triggers (sedation, ulceration, advanced disease)
ESD may be denied if the patient is not a candidate for procedural sedation or anesthesia, the lesion is ulcerated with features indicating high risk of lymph‑node metastasis or non‑curative resection, or disease exceeds accepted early‑stage criteria.
- Confirm patient is a candidate for sedation/anesthesia before scheduling; document candidacy in the record.
- Avoid submitting ESD requests when lesions show ulceration with endoscopic or histologic high‑risk features.
Post‑procedure pathology findings that may lead to denial or further management
Post‑procedure pathology that demonstrates positive margins (non‑R0), lymphovascular invasion, deep submucosal invasion (≥ sm2), or poorly differentiated cancers renders the resection non‑curative and may trigger denial of ESD as definitive therapy and prompt requirement for additional management.
- Document and submit post‑procedure pathology; if any non‑curative features are present, note that additional surgical or oncology evaluation is required.
- Site‑specific exclusions (gastric, esophageal, colorectal) list additional conditions that preclude coverage and should be documented.
Duodenal/small‑bowel ESD outside criteria is investigational — document justification or seek prior plan approval
Duodenal or small‑bowel ESD performed outside the policy’s specified medical necessity criteria (e.g., routine use, ampullary lesions, suspected deep submucosal invasion, lesions appropriate for EMR, or use for training) is classified as experimental/investigational and may be denied; individual case review with prior plan approval is required for investigational requests.
- For non‑ampullary duodenal/small‑bowel lesions, ensure documentation meets the strict criteria in the policy (mucosa‑confined, non‑invasive, not amenable to EMR, and EMR is unlikely to achieve complete resection).
- Requests outside these conditions require prior plan approval via individual case review.
Robotic‑assisted/computer‑enhanced ESD platforms are excluded (may be denied)
Procedures using robotic‑assisted or computer‑enhanced ESD platforms are classified as experimental/investigational and are not considered medically necessary; such procedures may be denied and require prior plan approval for any individual consideration.
- Do not submit robotic/computer‑enhanced ESD as standard ESD coverage—these platforms are explicitly excluded from coverage.
- If considering such a platform under investigational circumstances, request individual case review and prior plan approval.
Clinical Context and Definitions
Endoscopic submucosal dissection (ESD) is an advanced endoscopic technique developed to achieve en bloc resection of superficial gastrointestinal neoplasia not amenable to EMR. The procedure involves marking the lesion, submucosal injection, circumferential mucosal incision, controlled submucosal dissection with an electrosurgical knife, and endoscopic hemostasis to permit complete single‑piece removal for accurate histopathologic assessment.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.